GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (OTCPK:ACHFF) » Definitions » Net-Net Working Capital

ACHFF (Arch Biopartners) Net-Net Working Capital : $-0.08 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Arch Biopartners Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Arch Biopartners's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $-0.08.

The industry rank for Arch Biopartners's Net-Net Working Capital or its related term are showing as below:

ACHFF's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 4.36
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Arch Biopartners Net-Net Working Capital Historical Data

The historical data trend for Arch Biopartners's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Net-Net Working Capital Chart

Arch Biopartners Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 -0.05 -0.06 -0.06 -0.07

Arch Biopartners Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.07 -0.07 -0.07 -0.08

Competitive Comparison of Arch Biopartners's Net-Net Working Capital

For the Biotechnology subindustry, Arch Biopartners's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arch Biopartners's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Biopartners's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Arch Biopartners's Price-to-Net-Net-Working-Capital falls into.



Arch Biopartners Net-Net Working Capital Calculation

Arch Biopartners's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Sep. 2023 is calculated as

Net-Net Working Capital(A: Sep. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.614+0.75 * 0+0.5 * 0-4.938
-0-0)/62.5988
=-0.07

Arch Biopartners's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

Net-Net Working Capital(Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.005+0.75 * 1.022+0.5 * 0-6.076
-0-0)/62.7556
=-0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Arch Biopartners  (OTCPK:ACHFF) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Arch Biopartners Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Arch Biopartners Business Description

Traded in Other Exchanges
Address
545 King Street West, Toronto, ON, CAN, M5V 1M1
Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.

Arch Biopartners Headlines

From GuruFocus